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3. HORAS5-BCL2A1: mechanism of action
1. LncRNA  H19 is highly upregulated in
tumorigenic PCa cells
4. Clinical evidence on H19 and HORAS5 and 
gene therapy using lncRNA-ASOs
2. HORAS5 promotes drug resistance   in CRPC 
cells via reduced caspase activity
1.Zhai, W. et al. Mol. Cancer, 2019.
2.Li, P. et al., Mol.Can.Ther., 2017.
3.Tan, D. et al., Nat. Med., 2017.
Long non-coding RNAs (lncRNAs) are the longest class of
ncRNAs (>200 nt) recently characterized as key players in
several cancer-associated processes such as tumorigenesis and
drug resistance1-3 . Emerging data indicate that lncRNAs affect
the progression of prostate cancer (PCa) and promotes the
formation of its aggressive and incurable forms, such as
castration resistant Pca (CRPC).
In the present study we show that lncRNA H19 is highly
upregulated in the context of PCa tumorigenesis and that
HORAS5 promotes CRPC drug resistance. Both lncRNAs are also
associated with clinical features, showing their translational
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Introduction Methods
1.H19 is upregulated in PCa in vivo tumorigenic cells and is co-expressed with PCa associated genes in patients.
2.HORAS5 overexpression increases CRPC drug resistance (IC50). HORAS5 silencing favours cabazitaxel-induced CRPC cell death.
3.HORAS5 inhibits cell death by upregulating the anti-apoptotic protein BCL2A1.
4.H19 and HORAS5 are associated with PCa clinical features (tumor grade and drug treatment, respectively) and patient poor
prognosis. LncRNA-targeting antisense gene therapy works in PCa cells and is a promising novel therapeutic approach in cancer.
• The Open University
• Cancer Research UK:22592 
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• RNA sequencing: Illumina and Ion Torrent NGS
• Gene expression analysis: Taqman RT-qPCR with HPRT1
as normalization control and ΔΔCt method.
• Drug treatment: PCa cells treated with cabazitaxel upon
HORAS5 RNAi or lentiviral-mediated overexpression.
• Trypan blue-based cell count and caspase 3/7 assay to
determine cell proliferation and apoptosis, respectively.
• Western blot (WB) with anti-BCL2A1 and anti-GAPDH
antibodies and Syngene Gbox with GeneTools software.
• Transfection with DsiRNAs (2nM) and ASOs (75nM) was
performed using RNAiMax.
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30.55 ± 3.9 
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nM
Figure2: DU145 and
LNCaP cell count and
IC50 (A,B) and caspase









and nonlinear fit was
used to calculate the
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Figure 3: RNA seq flowchart of DU145-OE (HORAS5 overexpression) cells vs
DU145-NC (negative control) (A) and qPCR and protein validation of BCL2A1 (B)
. Cell count (C) and apoptosis assay (caspase 3/7, D) upon BCL2A1 silencing and
cabazitaxel treatment. Results as means ± S.D. from three independent
replicates. Statistics: One way anova with Tukey`s post-test:
*P<0.05,**P<0.01,***P<0.001,****P<0.0001. WB: Syngene Genesys tool.
Figure1: A. Flowchart of H19 selection and qPCR validation of RNA-Seq data
from sequencing of E006AA (non tumorigenic in nude mice) vs E006AA-ht
(highly tumorigenic). B. H19 is positively coexpressed with PCa regulating






Figure 3: H19 RNA seq expression upon PCa grades (A) and association with disease-free
survival (B). HORAS5 microarray expression upon taxanes treatment on Pca patients and
association with disease-free survival (D). HORAS5 inhibition with ASO decreases cell
count in cabazitaxel treated cells (E) and reduces the IC50 (F). Results as means ± S.D. from
three independent replicates. Statistics: One way anova with Tukey`s post-test: *P<0.5 (A).
Student’s t-test: **P<0.01 (C, F). 2way anova with Sidak`s post-test: **P<0.01 (E).
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